Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease…

Overview of attention for article published in Orphanet Journal of Rare Diseases, July 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#6 of 2,630)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 40 news outlets

Readers on

mendeley: 14 Mendeley

So far, Altmetric has seen 46 news stories from 40 outlets.

Pharnext Completes Patient Enrollment in International Pivotal Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A

El Economista, 20 Dec 2016

Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of…

Pharnext Completes Patient Enrollment in International Pivotal Phase 3 Trial of PXT3003 for...

Fresh News, 20 Dec 2016

Pharnext Completes Patient Enrollment in International Pivotal Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A…

News story from Finanz Nachrichten on Tuesday 20 December 2016

Finanz Nachrichten, 20 Dec 2016

Pharnext Completes Patient Enrollment in International Pivotal Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A

BioMed Reports, 20 Dec 2016

Dec. 20, 2016 07:00 UTC PARIS--( BUSINESS WIRE )-- Regulatory News: Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a French…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 42 additional news stories.